Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 6Cyclophosphamide 6fludarabine phosphate 5Nivolumab 5Mycophenolic Acid 5Carboplatin 5Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cyclosporine 4Gemcitabine 3Cisplatin 3Busulfan 3Antilymphocyte Serum 3cabozantinib 2cabazitaxel 2Voriconazole 2Thiotepa 2Therapeutics 2Standard of Care 2Sirolimus 2Polymerase Chain Reaction 2Mitomycin 2Methylprednisolone 2Methotrexate 2Melphalan 2Itraconazole 2Immunoglobulin G 2Goserelin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × VGX-3100 × Genitourinary × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡